ABOLERIS PHARMA
AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance.
ABOLERIS PHARMA
Social Links:
Industry:
Biotechnology
Founded:
2019-01-01
Address:
Nantes, Pays De La Loire, France
Country:
France
Website Url:
http://www.aboleris-pharma.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
2.5 M EUR
Technology used in webpage:
Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Shutterstock
Similar Organizations
Anjarium Biosciences
Anjarium is focused on creating new class of non-viral gene therapies to deliver predictable ,inclusionary ways to tackle genetic diseases.
Rainier Therapeutics
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Current Employees Featured
Founder
Investors List
Newton Biocapital
Newton Biocapital investment in Seed Round - AbolerIS Pharma
Sham Innovation Santé
Sham Innovation Santé investment in Seed Round - AbolerIS Pharma
Official Site Inspections
http://www.aboleris-pharma.com
- Host name: 217-160-0-102.elastic-ssl.ui-r.com
- IP address: 217.160.0.102
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "AbolerIS Pharma"
About us - Aboleris Pharma
Carole is co-founder and Head of Research of AbolerIS Pharma. After a PhD, Carole joined the laboratory of Pr Doherty, Nobel Prize winner in medicine, in Australia, thanks to a European …See details»
AbolerIS Pharma - Crunchbase Company Profile & Funding
AbolerIS Pharma may be growing as it has successfully secured a significant amount of funding, specifically €27.3 million in Series A financing. This influx of capital is indicative of investor …See details»
AbolerIS Pharma - Org Chart, Teams, Culture & Jobs
AbolerIS Pharma will develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune and degenerative diseases. Anti-CD45RC monoclonal antibody …See details»
Contact - Aboleris Pharma
[email protected]. Belgium. AbolerIS Holdco SA. Rue Antoine de Saint Exupéry 14. 6041 Gosselies. VAT number: BE 0803.217.012See details»
AbolerIS Pharma Announces Formation of Scientific Advisory Board
Apr 24, 2025 AbolerIS Pharma is a clinical-stage biopharmaceutical company committed to improving the lives of patients suffering from autoimmune and inflammatory diseases. The …See details»
AbolerIS Pharma - BioWin
The AbolerIS team is composed of scientific founders with decades of experience in basic and translational immunology and a strong leadership team with experienced biotech leaders and …See details»
AbolerIS Pharma 2025 Company Profile: Valuation, Funding
AbolerIS Pharma has raised $49.9M. Who are AbolerIS Pharma’s investors? Criteria Bio Ventures , Investsud , SambrInvest , Société Fédérale de Participations et d'Investissement, and Sound …See details»
About us - Aboleris Pharma
Founded by three prestigious scientists, Dr. Carole Guillonneau, Dr. Ignacio Anegon, and Dr. François-Xavier Hubert, AbolerIS Pharma is developing novel and unique therapeutic …See details»
Home - Aboleris Pharma
AbolerIS Pharma is developing a first-in-class monoclonal antibody based on a novel scientific approach to restore the balance in the immune system. Our novel and unique therapeutic …See details»
Carole Guillonneau - Founder at AbolerIS Pharma - The Org
Carole Guillonneau is an accomplished researcher and co-founder of AbolerIS Pharma, serving as Head of Research since November 2019. Carole is also the Director of the FOCIS Center …See details»
ABOLERIS PHARMA - Atlanpole Biotherapies
AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune and …See details»
Investors - Aboleris Pharma
AbolerIS Pharma isn’t just a biotech company; we’re pioneers of medical transformation. Our commitment to advancing healthcare is deeply rooted in groundbreaking science that drives …See details»
ABOLERIS PHARMA - Ouest Valorisation
AbolerIS Pharma lève 27.3M€ en 2023. En 2023, suite à un premier tour de table de 2,5 M réalisé en 2020, la biotech lève 27,3 M€ lui permettant d’accélérer le développement de sa …See details»
AbolerIS Pharma Announces Formation of Scientific Advisory Board
Apr 29, 2025 AbolerIS Pharma is a clinical-stage biopharmaceutical company committed to improving the lives of patients suffering from autoimmune and inflammatory diseases. The …See details»
Aboleris Pharma - Biotech Careers
AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune and …See details»
AbolerIS Pharma - Contacts, Employees, Board Members
AbolerIS Pharma has 6 current employee profiles, including CEO Ann Meulemans. Ann Meulemans CEO. Carole Guillonneau Co-founder. Tomas Van Dyck Chief Financial Officer. …See details»
Our Science - Aboleris Pharma
AbolerIS Pharma is a beneficiary of the REACT-EU program. We has received almost €1.5 million in support for the CMC and preclinical program of its lead compound ABIS-45RC, an anti …See details»
First cohort dosed with AbolerIS’ ABO21009 in RA treatment trial
5 days ago AbolerIS Pharma noted that ABO21009 stems from the company’s immunomodulatory approach for treating inflammatory and autoimmune conditions. The …See details»
AbolerIS Pharma Announces First Cohort Dosed in Phase 1 Study …
May 7, 2025 GOSSELIES, Belgium and NANTES, France, May 7, 2025 /PRNewswire/ -- AbolerIS Pharma ("AbolerIS"), a clinical-stage biopharmaceutical company committed to …See details»
AbolerIS Pharma Announces €27 Million in Series A Financing to …
Sep 17, 2023 Gosselies, Belgium, September 18, 2023: AbolerIS Pharma (“AbolerIS”), a Belgian biopharmaceutical company developing an entirely novel approach to the treatment of chronic …See details»